Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J8BZ
|
|||
| Former ID |
DNCL002743
|
|||
| Drug Name |
BIIB 2024
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2] | |
| Gastrointestinal stromal tumour [ICD-11: 2B5B] | Phase 2 | [1], [2] | ||
| Company |
Biogen Idec
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00574236) Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013 Jan;24(1):252-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.